Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

The concept you're suggesting involves the poten

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154722
(Total Views: 437)
Posted On: 03/05/2024 7:10:08 PM
Posted By: biloxiblues
Re: chazzledazzle #141544

The concept you're suggesting involves the potential role of CCR5 receptors in Alzheimer's disease and the potential therapeutic effect of blocking these receptors using a drug like Leronlimab.

If blocking CCR5 receptors could restore or block memory windows in Alzheimer's disease, and if Leronlimab effectively occupies CCR5 receptors at a significant rate (72% as you suggested), then it could indeed have potential as a therapeutic intervention for Alzheimer's disease.

However, it's important to note that the relationship between CCR5 receptors and Alzheimer's disease is still not fully understood, and the potential therapeutic effects of blocking these receptors are largely speculative at this point. While some research has suggested a link between CCR5 and Alzheimer's disease, the exact mechanisms involved and the potential therapeutic benefits of targeting CCR5 are still under investigation.

Additionally, the effectiveness and safety of Leronlimab or any other CCR5-blocking drug would need to be thoroughly studied in clinical trials before it could be considered a viable treatment for Alzheimer's disease. Such trials would need to assess not only the drug's ability to occupy CCR5 receptors but also its impact on the progression of Alzheimer's disease symptoms, as well as any potential side effects or safety concerns.







(4)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us